SCROLL DOWN
gene therapy for phagocyte disorders
01
02
03
04
Our platform utilizes lentivirus-transduced stem cells to offer safe and effective therapies for potentially more than 50 known genetic disorders. The specific safety of our one-time treatment lies in its exclusive activity within terminally differentiated cells.
KEEP SCROLING
01
Every day, we work towards our vision of a world where genetic diseases can be effectively treated. The company’s proprietary platform technology challenges the limitations of traditional gene therapies by ensuring unprecedented safety and cellular specificity while maintaining therapeutic effectiveness. Our approch has the potential to cure a wide range of phagocyte disorders, significantly improving the lives of thousands of patients globally.
02
Our innovative research is showing significant promise in GLP-compliant preclinical animal studies. Our lead therapy, SGX-001, is on track to enter human clinical trials in 2026, with the goal of curing Chronic Granulomatous Disease (CGD) — a serious immune deficiency with no lasting treatment options. We are driven by a commitment to extend our breakthroughs to other inherited diseases and neurodegenerative disorders
2026
SGX-001
01
Our team at Somagenetix brings together a wealth of experience in gene therapy, immunology, and clinical research. United by a shared vision, we are dedicated to pushing the boundaries of science to deliver life-changing treatments for genetic disorders.
02
Somagenetix presents a unique investment opportunity, driven by innovative gene therapy. Its lead product, SGX-001, has completed pre-clinical development with strong safety and efficacy results, meeting FDA and EMA standards. Additionally, it holds Orphan Drug Designation in both the U.S. and Europe, highlighting its potential to address critical unmet medical needs.
Stay informed with the most recent updates from Somagenetix. In our News section, you’ll find the latest on our research developments, clinical trial milestones, industry partnerships, and more
Whether you’re a patient seeking information, a healthcare provider interested in our therapies, or an investor looking for opportunities, we’re here to help. Contact us to learn more about how we can work together to transform the future of healthcare.
